NEWTON, Mass. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) and Quintiles Transnational Corp. today announced a strategic alliance to offer to Quintiles’ customers CLDA’s proprietary services related to the evaluation of drug-induced QT prolongation. The pharmacogenomics analyses are performed in the New Haven, CT, laboratories of Clinical Data’s service division, Cogenics™. As part of the alliance, the two companies may also collaborate on the study of drug-induced QT prolongation for potential development of new products or services. This multi-year agreement will help sponsors and regulatory agencies further the understanding of the contribution of genetics to the QT-prolonging effects of drugs. Financial terms of the agreement were not disclosed.
